>
No Escape From Washington's Fiscal Doomsday Machine
New Questions about Pilot's Mental Health After Air India Crash Looks to Be INTENTIONAL
Ross Ulbricht 2.0: Roman Storm Faces 40 Years for Writing Code to Protect Your Privacy
Magic mushrooms may hold the secret to longevity: Psilocybin extends lifespan by 57%...
Unitree G1 vs Boston Dynamics Atlas vs Optimus Gen 2 Robot– Who Wins?
LFP Battery Fire Safety: What You NEED to Know
Final Summer Solar Panel Test: Bifacial Optimization. Save Money w/ These Results!
MEDICAL MIRACLE IN JAPAN: Paralyzed Man Stands Again After Revolutionary Stem Cell Treatment!
Insulator Becomes Conducting Semiconductor And Could Make Superelastic Silicone Solar Panels
Slate Truck's Under $20,000 Price Tag Just Became A Political Casualty
Wisdom Teeth Contain Unique Stem Cell That Can Form Cartilage, Neurons, and Heart Tissue
Hay fever breakthrough: 'Molecular shield' blocks allergy trigger at the site
The one-two punch provided by the novel approach could pave the way for earlier detection and more effective treatment of the disease.
With an average five-year survival rate of less than 10%, pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer. It's also difficult to detect using conventional imaging methods, including positron emission tomography (PET) scans.
Now, researchers at Osaka University in Japan have developed a strategy for combatting this deadly cancer by combining therapeutics and diagnostics – 'theranostics' – into a single, integrated process.
The process developed by the researchers uses radioactive monoclonal antibodies (mAb) to target glypican-1 (GPC1), a protein highly expressed in PDAC tumors. GPC1 has been implicated in cancer cell proliferation, invasion, and metastasis, and high expression of the protein is a poor prognostic factor in some cancers, including pancreatic cancer.
"We decided to target GPC1 because it is overexpressed in PDAC but is only present in low levels in normal tissues," said Tadashi Watabe, the study's lead author.
The researchers injected human pancreatic cancer cells into mice, allowing them to develop into a full tumor. The xenograft mice were administered intravenous GPC1 mAb labeled with radioactive zirconium (89Zr) and observed for antitumor effects.
"We monitored 89Zr-GPC1 mAb internalization over seven days with PET scanning," said Kazuya Kabayama, the study's second author. "There was strong uptake of the mAb into the tumors, suggesting that this method could support tumor visualization. We confirmed that this was mediated by its binding to GPC1, as the xenograft model that had GPC1 expression knocked out showed significantly less uptake."